AcuraStem’s AS-202 for ALS Shows Promise in Preclinical Studies

AcuraStem’s AS-202 for ALS Shows Promise in Preclinical Studies

316235

AcuraStem’s AS-202 for ALS Shows Promise in Preclinical Studies

AcuraStem’s experimental therapy AS-202 significantly reduced neurodegeneration and improved motor function and survival in a mouse model of aggressive amyotrophic lateral sclerosis (ALS) associated with toxic clumps of the TDP-43 protein, the company announced. Preclinical studies also confirmed the therapy’s biological activity and target engagement and suggested that it has a favorable safety profile. “These data make AS-202 a very promising drug candidate for the 97% of ALS patients that present with [TDP-43-related damage],” Peter…

You must be logged in to read/download the full post.